Friday 6 November 2026 Export TEM’s income statement to Excel — free account

Tempus AI, Inc.

TEM Healthcare Health Information Services

Tempus AI, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 83.4% from fiscal 2024.

Revenue: +23.1%
EPS: +82.2%
Free cash flow: +95.7%
Total debt: +8.44%

Quarter to September 2026, against a year earlier

75.66 5.23 +7.43%

Follow TEM

Alert me

Market cap: $12.9B
P/E: 0.0×
Fwd P/E: −51.8×
Dividend yield: —
F-score: 4/9
Altman Z: 2.60
Beneish M: −1.25
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Tempus AI, Inc. (TEM) revenue by segment, product and region

Revenue by product or service $m

Line	FY2025	FY2024
Diagnostics	955 75.12%	452 65.15%
Insights Product	258 20.26%	187 26.94%
Trials Product	39 3.03%	42 6.11%
AI Applications	20 1.58%	12 1.77%
Data and applications	316	242
Revenue	1,272	693

Gross profit by product or service $m, and margin

	FY2025	FY2024
Diagnostics	‡	‡
Data and applications	‡	‡
Gross profit	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡
	‡	‡

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Hereditary testing unit growth	Q1 FY2026	54.0%	23.0%	—
MRD volume	Q3 FY2026	12.0K	—	—
Oncology testing volume growth	Q3 FY2026	32.0%	27.0%	—

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025
Hereditary testing unit growth	‡	‡	‡	‡	‡	‡	‡
MRD volume	‡	‡	‡	‡	‡	‡	‡
Oncology testing volume growth	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.